Influence of hormonal therapy on the level of prostate specific antigen in patients with advanced prostatic cancer

Vojinov, Sasa; Marusic, G.; Levakov, Ivan; Popadic-Gacesa, Jelena

doi:10.2298/mpns1008479v

Cited by 3 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…last checkup (after 12 weeks on sildenafil treatment). Our findings were not confirmed in most other studies [6][7][8][9][10][11][12][13][14]: Qmax was not significantly different comparing to placebo.…”

Section: Discussioncontrasting

confidence: 99%

“…In our study we have found that the mean value of IPSS improved from 12.8 at the beginning of study to 9.0 (29.6% change) and 8.6 (32.8% change) at the first checkup (six weeks on sildenafil treatment) and at the second/last checkup (after 12 weeks on sildenafil treatment), respectively. In most randomized, placebo controlled studies, which were conducted lately, the efficiency of all three PDE5 inhibitors was observed through IPSS, Qmax and PVR changes [6][7][8][9][10][11][12][13][14][15]. Maximal time frame of studies was 12 weeks.…”

Section: Discussionmentioning

confidence: 99%

“…last checkup (after 12 weeks on sildenafil treatment), respectively. In almost all other studies there were no significant changes of PVR [6][7][8][9][10][11][12][13][14]. There are few studies with significant improvement of Qmax.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Efficiency of sildanefil monotherapy in benign prostatic hyperplasia

et al. 2016

Self Cite

View full text Add to dashboard Cite

Treatment of benign prostatic hyperplasia and lower urinary tract symptoms with a continuous low dose of sildenatil seems to be a good treatment choice for the patients with mild to moderate benign prostatic hyperplasia and lower urinary tract symptoms, especially in the patients with concomitant erectile dysfunction. The authors are aware that their study is limited by a small number of patients. Since there are not too many studies on this topic, they believe that their study will contribute to the determination of place and role of this treatment approach.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficiency of sildanefil monotherapy in benign prostatic hyperplasia

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…27 Phadke i sar. 28 navode da postoji sniženje LH kod uznapredovalog karcinoma u odnosu na bolesnike sa benignom hiperplazijom prostate, što odgovara rezultatima naše prethodne studije 29 . Niži nivo LH može se objasniti direktnim uticajem karcinomskih ćelija na serumski LH (produkcija materija koje snižavaju LH u serumu od strane karcinoma) ili indirektno, kao posledica dediferencijacije kojom se gubi normalna (stimulatorna) funkcija zdrave prostate na homeostazu LH.…”

Section: Diskusijaunclassified

Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade

et al. 2011

Self Cite

View full text Add to dashboard Cite

Total androgen blockade and LH-RH agonists are more effective in lowering testosterone values (to castration values) compared to the antiandrogen monotherapy, where testosterone values stay above the castration level. This therapy approach has advantages, since it decreases testosterone values providing better therapy response. There is a difference in testosterone values, but not significant, when total androgen blockade and monotherapy with LH-RH agonists are administered. Registered lower basal values of LH in all patients with prostatic cancer open the possibility to introduce LH as a new additional, significant marker in diagnosis of this neoplasm.

show abstract

Postoperative influence of interferon alpha on patients with renal cell carcinoma

et al. 2011

Self Cite

View full text Add to dashboard Cite

The aim of this study was to show whether immunotherapy should be administered in patients with renal cell carcinoma after radical nephrectomy in N0 and N1 stage of disease. The research was conducted in 60 patients with renal adenocarcinoma after radical nephrectomy. The study group included two subgroups of patients: the treatment group consisted of 30 patients receiving immunotherapy, of whom 15 had N1 disease stage and 15 had N0 disease stage; and the observation group consisted of 30 patients who did not receive immunotherapy, of whom 15 had N1 disease stage and 15 had N0 disease stage. It was shown that the administration of immunotherapy in N0 stage neither improved the overall survival nor postponed the appearance of metastases and that immunotherapy in N1 stage even worsened the prognosis in overall survival as compared with the observation group. There is no benefit of administering immunotherapy in patients with N0 and N1 stage of disease after radical nephrectomy.

show abstract

Influence of hormonal therapy on the level of prostate specific antigen in patients with advanced prostatic cancer

Abstract: Although prostate specific antigen is not a prostatic cancer specific parameter; the dynamics of its decrease during the therapy of androgen blockade represents a significant marker of the therapy effect.

Cited by 3 publications

References 10 publications

Efficiency of sildanefil monotherapy in benign prostatic hyperplasia

Efficiency of sildanefil monotherapy in benign prostatic hyperplasia

Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade

Postoperative influence of interferon alpha on patients with renal cell carcinoma

Contact Info

Product

Resources

About